Truffle Capital is a venture capital and private equity firm specializing in startup, post start up, growth capital, investments in spins offs from initial round to the pre-exit round, LBOs, and PIPEs. The firm invests in information technology, energy, life sciences, telecommunication, electronics, and biotechnology and pharmaceuticals. In information technology, it focuses on mobile content and connectivity, Internet, technical software, IT security, VOIP, and security and technical software. Within energy, the firm typically invests in energy efficiency, energy management, new technologies for traditional energies, and renewable energy like solar, wind, wave power, tidal power, mini-hydro...
5, rue de la Baume
Founded in 2001
Truffle Capital Announces Creation of ABIVAX in Collaboration with the Cuban Center for Genetic Engineering and Biotechnology
Feb 12 14
Truffle Capital has announced the creation of ABIVAX in collaboration with the Cuban Center for Genetic Engineering and Biotechnology (CIGB). This is the first ever start-up launched on the basis of a Euro-Cuban R&D collaboration. The goal of ABIVAX is to become a global leader in therapeutic vaccines and antivirals, leveraging both its existing product pipelines and future acquisitions that are currently in negotiations. ABIVAX specializes in therapeutic vaccines and antivirals, combining the technologies and the product portfolios of three French biotech companies financed by Truffle Capital (Wittycell, Splicos and Zophis). An exclusive partnership agreement with the CIGB has been approved by the Cuban government and will further enrich the portfolio. The CIGB is a subsidiary under BioCubaFarma that specializes in the discovery, development and production of vaccines and antivirals. ABIVAX already possesses several key assets including complementary technology platforms, a high-value product portfolio and an experienced top management team.